Who are Simponi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Trulance, Lymphostat B, Prolia, Abrilada, Humira.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/golimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Simponi — Competitive Intelligence Brief

Simponi (GOLIMUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tumor Necrosis Factor Blocker [EPC]. Area: Oncology.

marketed Tumor Necrosis Factor Blocker [EPC] Tumor necrosis factor Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Simponi (GOLIMUMAB) — Centocor Ortho Biotech Inc. Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Simponi TARGET	GOLIMUMAB	Centocor Ortho Biotech Inc	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Elrexfio	elranatamab-bcmm	Pfizer	marketed		Tumor necrosis factor receptor superfamily member 17	2023-01-01
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Lymphostat B	BELIMUMAB	Human Genome Sciences Inc.	marketed	B Lymphocyte Stimulator-specific Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 13B	2011-01-01
Prolia	DENOSUMAB	Amgen	marketed	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	2010-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01

Recent regulatory actions (last 90 days)

2026-02-19 — Elrexfio · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tumor Necrosis Factor Blocker [EPC] class)

SAMSUNG BIOEPIS CO LTD · 2 drugs in this class
COHERUS BIOSCIENCES INC · 1 drug in this class
Centocor Ortho Biotech Inc · 1 drug in this class
Immunex · 1 drug in this class
Johnson & Johnson · 1 drug in this class
SANDOZ INC · 1 drug in this class
· 1 drug in this class
UCB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simponi — Competitive Intelligence Brief. https://druglandscape.com/ci/golimumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab